Skip to main content
. 2014 Mar 28;17(1):61–68. doi: 10.4048/jbc.2014.17.1.61

Figure 4.

Figure 4

Overall response rate (ORR) and clinical benefit analysis of sorafenib for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer compared with placebo. ORR and clinical benefit rate were significantly higher in treatment group compared with placebo group (hazard ratio [HR], 1.19, 95% confidence interval [CI], 1.01-1.39, p=0.03; HR, 1.23, 95% CI, 1.03-1.45, p=0.02).

M-H=Mantel-Haenszel.